|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00293527 |
|
Date of registration:
|
15/02/2006 |
|
Primary sponsor: |
|
|
Public title:
|
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
|
|
Scientific title:
|
A Phase II Dose Escalation Study of Continuous Daily Subcutaneous Administration of Interferon Alpha-2b in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma |
|
Date of first enrolment:
|
February 2006 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
http://clinicaltrials.gov/show/NCT00293527 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Thomas Olencki |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Ohio State University |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Metastatic or unresectable clear cell renal cell carcinoma
- Measurable disease
Exclusion Criteria:
- Prior interferon therapy
- More than 3 prior therapy regimens
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Renal Cancer
|
|
Intervention(s)
|
|
Drug: Interferon Alpha-2b
|
|
Secondary ID(s)
|
|
OSU-05030
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|